Kolistimetatnatrium Noridem

Colistimethate Sodium, the active ingredient in Kolistimetatnatrium Noridem, is a polymyxin presented as a sterile injectable solution for intracerebroventricular and intrathecal use. It treats severe infections caused by Gram‑negative bacteria, including central nervous system infections, when administered directly into the cerebrospinal fluid.

GNH USA supplies Kolistimetatnatrium Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, providing quality‑assured batches to healthcare institutions across multiple regions.

Kolistimetatnatrium Noridem is a polymyxin antibiotic used for serious Gram‑negative bacterial infections that require direct central nervous system delivery.

- Severe Gram‑negative infections: eradicates multidrug‑resistant organisms in systemic infections. - Bacterial meningitis: achieves therapeutic concentrations in cerebrospinal fluid when given intrathecally. - Ventriculitis: treats infection of the ventricular system via intracerebroventricular administration. - Post‑neurosurgical infections: provides targeted antimicrobial activity in the CNS after surgical procedures.

Adverse reactions may occur with intrathecal or intracerebroventricular administration of colistimethate sodium.

Common Side Effects: - Headache: mild to moderate discomfort. - Nausea: transient gastrointestinal upset. - Fever: low‑grade temperature elevation. - Local irritation: pain or redness at the injection site. - Dizziness: temporary vertigo or light‑headedness. - Transient increase in cerebrospinal fluid protein.

Serious or Rare Side Effects: - Neurotoxicity: seizures, altered mental status, or peripheral neuropathy. - Nephrotoxicity: acute kidney injury with elevated serum creatinine. - Respiratory distress: bronchospasm or respiratory failure. - Anaphylaxis: severe allergic reaction with hypotension and airway compromise.

Colistimethate sodium requires careful monitoring due to its narrow therapeutic index and potential toxicity.

- Renal function: assess baseline creatinine and monitor during therapy. - Neurological status: observe for signs of neurotoxicity such as seizures. - Concomitant nephrotoxic drugs: avoid or adjust dosing when used with other renal‑impairing agents. - Electrolyte balance: monitor serum potassium and magnesium levels. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Colistimethate sodium may interact with other medications, affecting safety or efficacy.

Major Interactions (Avoid): - Aminoglycosides: combined nephrotoxicity and neurotoxicity risk. - Loop diuretics: increased risk of renal impairment. - Neuromuscular blocking agents: potentiation of neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate renal dysfunction. - Vancomycin: additive nephrotoxic potential. - Corticosteroids: may mask signs of infection or alter immune response.